Houlihan Lokey is pleased to announce that the shareholders of Cancerscan Inc. (Cancerscan) have agreed to be acquired by JMDC Inc. (JMDC) at an equity value of approximately US$100 million. The transaction is expected to close in January 2024.
Founded in 2008 and headquartered in Tokyo, Japan, Cancerscan is a leading healthcare data services provider that supports the National Health Insurance Association (NHIA) of Japan to raise public health checkup rates through its unique behavioral-science-based solution. In just nine years, Cancerscan succeeded in establishing solid relationships with more than 700 of the approximately 1,700 municipalities across Japan, promoting health screening, disease management and prevention, and extension of overall healthy life expectancy by utilizing collective data. It had revenue of approximately US$30 million and an operating profit of about US$5 million last fiscal year.
Founded in 2002 and headquartered in Tokyo, Japan, JMDC (TYO:4483), is a healthcare statistics and data services company that utilizes health checkup data from the Employee Health Insurance Association (EHIA) to help maintain and promote the health of company workers through preventive and pre-symptomatic medicine.
This transaction allows Cancerscan to extend its know-how to JMDC’s client base, promoting positive shifts in people’s behavior towards regular checkups and better self-care, with the long-term goal of realizing a sustainable healthcare system using data and ICT to address key issues in the healthcare space. Furthermore, Cancerscan and JMDC will be able to provide higher quality services by combining their databases in the NHIA and EHIA markets, which will contribute highly to the extension of a healthy life expectancy and the reduction of medical costs in Japan in the longer term.
Houlihan Lokey is serving as the exclusive financial advisor to the shareholders of Cancerscan. This transaction highlights the firm's extensive expertise in the healthcare data services space.
If you would like more information about Houlihan Lokey or have questions regarding the firm’s role in this transaction, please contact the team members listed below. | 
